Home / Biopharma / Biotech Stocks Wining High Volatility- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Biotech Stocks Wining High Volatility- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) [Trend Analysis] plunged over 3.8% in pre trading session as the U.S. FDA has permitted first drug that plans to treat one of more disruptive symptoms of Parkinson’s disease. Parkinson’s disease psychosis, a symptom that affects an estimated 40% of sufferers, causes hallucinations and delusions, and the stress it creates for caregivers has made it one of the main reasons for Parkinson’s patients to be placed in nursing homes.

The drug, Nuplazid is made by Acadia Pharmaceuticals Inc. (ACAD), a biopharma that specializes in developing treatments for disorders of the central nervous system for which there are currently no available therapies. The FDA had already designated the drug, also known as pimavanserin, a breakthrough therapy for Parkinson’s disease psychosis in 2014, Acadia said in a statement. The company will make the drug available in its specialty pharmacies in June.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) retains strong position in active trade, as shares scoring 2.17% to $33.00 in a active trade session, while looking at the shares volume, around 8.11 Million shares have changed hands in this session. The firm has institutional ownership of 91.00%, while insider ownership included 0.20%. ACAD attains analyst recommendation of 1.70 with week’s performance of -3.45%. Investors looking further ahead will note that the Price to next year’s EPS is 42.10%.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) [Trend Analysis] declared that its financial results for Q1 ended March 31, 2016. Total revenues for the quarter ended March 31, 2016 were approximately $6.8 million, compared with $1.2 million during the same period in 2015. Total revenues for the quarter consisted of Auryxia net U.S. product sales of $5.6 million, and license revenue of $1.2 million associated with royalties received on ferric citrate net sales from Keryx’s Japanese partner. Cost of goods sold for the quarter ended March 31, 2016 was $1.1 million or 19 percent of Auryxia net U.S. product sales, as compared with $0.1 million or 18 percent during the same period in 2015.

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) knocking active thrust in leading trading session, shares a gain of 9.56% to 5.96 with around 2.83 Million shares have changed hands in this session. The stock is going forward its fifty-two week low with 112.86% and lagging behind from its 52-week high price with -47.35%.  Likewise the positive performance for the quarter recorded as 75.81% and for the year was -45.32%, while the YTD performance remained at 18.02%. KERX has Average True Range for 14 days of 0.41.

About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Check Also

Stocks Faring Away From Broker’s Choice: Opko Health (NASDAQ:OPK), Shire plc (NASDAQ:SHPG)

Several matter pinch shares of Opko Health, Inc. (NASDAQ:OPK) [Trend Analysis], as shares plunging -2.56% …

Leave a Reply

Your email address will not be published. Required fields are marked *